查詢結果分析
來源資料
頁籤選單縮合
題 名 | Tamoxifen治療包囊性腹膜硬化症文獻回顧=A Literature Review of Tamoxifen Treatment of Encapsulating Peritoneal Sclerosis |
---|---|
作 者 | 楊麗柔; 彭姿蓉; | 書刊名 | 藥學雜誌 |
卷 期 | 34:1=134 2018.03[民107.03] |
頁 次 | 頁79-84 |
分類號 | 415.57 |
關鍵詞 | 包囊性腹膜硬化症; 腹膜透析; Tamoxifen; Tncapsulating peritoneal sclerosis; Peritoneal dialysis; |
語 文 | 中文(Chinese) |
中文摘要 | 目的:包囊性腹膜硬化症 (encapsulating peritoneal sclerosis,EPS) 在長期接受腹膜 透析的病人,罕見但死亡率很高的疾病,目前臨床治療常使用藥物或進行手術,而藥 物又常以 tamoxifen 為選擇,但少有一致性的使用劑量及使用時間相關之報告。因此 藉由文獻回顧及討論,來探討 tamoxifen 用於治療腹膜透析相關 EPS,並提供臨床建 議。 方法:本文搜尋電子資料庫包括 Pubmed、Cochrane library 及手動搜尋,皆搜尋至 2017年1月前,搜尋條件限制英文、人類、評論性文章、研究報告,排除案例報告、 書信等型式文章及無電子或紙本全文之文獻。 結果:經二位作者擬訂關鍵字及搜尋文獻,交叉比對搜尋結果,符合條件有7篇, 分別為評論性文章3篇、研究性文章4篇。根據文獻評讀後則建議 tamoxifen 使用劑量 為10-40 mg/day 持續至少一年,結果能降低死亡率。 結論:由於此次搜尋文章,僅搜尋到評論性及研究性文章,研究性文章都為回溯 性研究,所以在藥物治療的選擇與療效之比較仍缺乏大型研究的證實,未來仍須仰仗 更嚴謹的隨機分派臨床試驗來研究與證實。 |
英文摘要 | Objective: Encapsulated peritoneal sclerosis (EPS) is a rare but high mortality disease for patients receiving long-term peritoneal dialysis (PD). Currently, the clinical therapeutic strategies often use of surgery or drugs, and tamoxifen is one of the most common drugs in treatment of EPS, but the reports have less consistent in the dose and duration of use. Therefore, we conducted a literature review to evaluate the efficacy of tamoxifen for treatment of PD associated with EPS, and further to provide clinical suggestions. Methods: The PubMed, Cochrane Library and manual search were electronically searched for relevant studies published until January 2017. The search was restricted to published English language, human, review or study papers, excluding case reports, letters or other types of articles and no electronic or full text literature. Results: Two authors defined keywords, searched database, and independently reviewed articles as well as extracted data. 7 articles are included in this review, respectively, 3 for the review and 4 for study articles. It was suggested that tamoxifen should be administered at a dose of 10-40 mg per day for the period of at least one year has demonstrated significantly reduced mortality in EPS patients after review of the literatures. Conclusion: Because of the searching only contained the review and study articles, and the studies are retrospective study. Therefore, the choice of drug therapy and efficacy is still lack of large-scale study to proven. It still need to rely on serious randomized-control trials to confirm the study in the future. |
本系統中英文摘要資訊取自各篇刊載內容。